U.S. president-elect Joe Biden, with vice-president-elect Kamala Harris, speaks about the COVID-19 crisis before introducing nominees to his incoming administration in Wilmington, Del., on Dec. 11, 2020. Biden is set to receive the COVID-19 vaccine on Monday.
JIM WATSON/AFP/Getty Images
The leader of the Trump administration’s vaccination program says people who have been infected with the coronavirus – a group that includes President Donald Trump – should receive the vaccine.
Moncef Slaoui, the chief adviser of Operation Warp Speed, told CNN’s State of the Union on Sunday that the vaccine is safe for those who have recovered and offers stronger and potentially longer protection than does the virus itself.
“We know that infection doesn’t induce a very strong immune response and it wanes over time. So I think, as a clear precaution, it is appropriate to be vaccinated because it’s safe,” he said. “I think people should be vaccinated, indeed.”
Story continues below advertisement
Trump is now one of the only senior-most U.S. officials who has not received the first of two vaccination shots, which began being administered last week as part of the largest vaccination campaign in the country’s history. Vice-President Mike Pence, House Speaker Nancy Pelosi, D-Calif., and Senate Majority Leader Mitch McConnell, R-Ky., all were given doses Friday. President-elect Joe Biden was to receive his Monday.
All have chosen to publicize their injections as part of a campaign to convince a skeptical public that the vaccines are safe and effective, in hopes of finally putting an end to a pandemic that has killed more than 317,000 people in the United States and upended life around the globe.
Trump, who in the past has spread misinformation about vaccine risks, tweeted earlier this month that he was “not scheduled” to take the vaccine, but looked “forward to doing so at the appropriate time.” The White House says he is still discussing timing with his doctors.
Trump was hospitalized with COVID-19 in October and given an experimental monoclonal antibody treatment that he credited for his swift recovery.
A Centers for Disease Control and Prevention advisory board has said people who received that treatment should wait at least 90 days to be vaccinated to avoid any potential interference.
“When the time is right, I’m sure he will remain willing to take it,” White House spokesperson Brian Morgenstern echoed Friday. “It’s just something we’re working through.”
Trump has spent the last week largely out of sight as he continues to stew about his election loss and floats increasingly outlandish schemes to remain in power. It’s an approach that has bewildered top aides who see his silence as a missed opportunity for the president, who leaves office Jan. 20, to claim credit for helping oversee the speedy development of the vaccine and to burnish his legacy.
Story continues below advertisement
Trump has also come under criticism for failing to take the vaccine himself as an example to help allay concerns about its safety, especially among Republicans.
The CDC’s Advisory Committee on Immunization Practices said the Pfizer-BioNTech vaccine, which was the first to receive authorization, “is safe and likely efficacious” in people who have been infected with COVID-19 and “should be offered regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection.”
While there is no recommended minimum wait time between infection and vaccination, because reinfection is uncommon in the three months after a person is infected, the committee said people who tested positive in the preceding 90 days “may delay vaccination until near the end of this period, if desired.”
But the advisers also recommended that those who received the kind of treatment Trump did should put off being vaccinated for at least 90 days.
“Currently, there are no data on the safety and efficacy of Pfizer-BioNTech COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment,” they wrote, recommending that vaccination “be deferred for at least 90 days, as a precautionary measure until additional information becomes available, to avoid interference of the antibody treatment with vaccine-induced immune responses.”
Surgeon General Jerome Adams cited that recommendation on CBS’s Face the Nation on Sunday when asked if Trump planned to receive the shot on camera.
Story continues below advertisement
“From a scientific point of view, I will remind people that the president has had COVID within the last 90 days. He received the monoclonal antibodies. And that is actually one scenario where we tell people maybe you should hold off on getting the vaccine, talk to your health provider to find out the right time,” Adams said.
White House press secretary Kayleigh McEnany has given other explanations for the delay. She told reporters last week that Trump was holding off, in part, “to show Americans that our priority are the most vulnerable.”
“The President wants to send a parallel message, which is, you know, our long-term care facility residents and our frontline workers are paramount in importance, and he wants to set an example in that regard,” she said.
Dr. Anthony Fauci, the nation’s top infectious diseases expert, is among those who have recommended that Trump be vaccinated without delay.
“Even though the president himself was infected, and he has, likely, antibodies that likely would be protective, we’re not sure how long that protection lasts. So, to be doubly sure, I would recommend that he get vaccinated,” he told ABC News.
Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.
TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.
Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.
Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).
SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.
The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.
WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.
SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.
SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.
SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.
The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.
Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.
“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.
“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”
Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.
On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.
If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.
These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.
If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.
However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.
He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.
“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.
Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.
The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.
Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.
Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.
Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.
Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.
Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”
In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.
“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.
This report by The Canadian Press was first published Nov. 12, 2024.
TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.
The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.
The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.
RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.
The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.
RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.
This report by The Canadian Press was first published Nov. 12, 2024.
/cloudfront-us-east-1.images.arcpublishing.com/tgam/IWH7YJTFDJPZFDG4B7HRFMY4VA.jpg)
